Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Chronic Lymphocytic Leukemia Clinical Trials

A listing of Chronic Lymphocytic Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (34) clinical trials

Biological Therapy in Treating Patients at High-Risk or With Lymphoma Lymphoproliferative Disease or Malignancies

OBJECTIVES: - Determine the toxicity and therapeutic potential of adoptive immunotherapy with Epstein Barr virus (EBV)-specific cytotoxic T lymphocytes derived from HLA-histocompatible related donors or haplotype-matched donor in the treatment of patients at high-risk or with EBV-induced lymphomas and other lymphoproliferative diseases or malignancies in immunocompromised hosts. - Complete a ...

Phase

Chemotherapy Followed by Allogeneic Stem Cell Transplantation in Treating Children With Hematologic Cancer

OBJECTIVES: Primary - Determine the efficacy and safety of non-myeloablative chemotherapy in facilitating donor engraftment after allogeneic stem cell transplantation with G-CSF mobilized peripheral blood stem cells in patients with pediatric hematopoietic malignancies. (Cohort 1) (closed to accrual as of 09/29/2005) - Determine the efficacy and safety of non-myeloablative chemotherapy ...

Phase

Combination Study of IPH2201 With Ibrutinib in Patients With Relapsed Refractory or Previously Untreated Chronic Lymphocytic Leukemia

This trial is designated to test the hypothesis that the combination of ibrutinib and IPH2201 will result in a substantial complete response (CR) rate, especially CR without minimal residual disease (MRD), as this has been shown to be associated with long-term clinical benefit. Up to 45 patients are planned to ...

Phase

The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)

The aim of this study is to determine whether the anti-CD74 monoclonal antibody Milatuzumab provides benefit to subjects with CLL in advanced stage or progressive disease. The primary objectives of this study are to assess response rate to the agent, as well as the safety in CLL, using different doses: ...

Phase

Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine

This will be a Phase I/II open-label, single-arm, dose-escalating, multicenter study, in three parts: Phase I Dose Escalation, Phase II, Part 1 RPTD Cohort, and Phase II, Part 2 Expansion, in which patients with myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), or chronic myelomonocytic leukemia (CMML) will receive subcutaneous (SC) ...

Phase

Fludarabine Busulfan and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disease

OBJECTIVES: - To assess the safety and feasibility of reduced-intensity preparative regimen comprising fludarabine, busulfan, and alemtuzumab followed by allogeneic hematopoietic stem cell transplantation in patients with hematological malignancies or other diseases. - To assess the rate of donor engraftment in patients treated with this regimen. OUTLINE: This is a ...

Phase

A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia

CLL is an incurable disease with current therapies. Modern chemoimmunotherapies, including combinations of rituximab and purine nucleoside analogues (fludarabine, cladribine, and pentostatin), offer the possibility for improved survival, but all patients will eventually relapse. Patients with relapsed or refractory disease will only experience diminishing benefits with additional lines of therapy. ...

Phase

Study of Idarubicin Cytarabine and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Study Groups: If you are found to be eligible to take part in this study, you will be assigned to a study group based on when you join this study. Up to 3 groups of 3 - 6 participants will be enrolled in Phase 1 of the study, and up ...

Phase

Phase I/II Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia

Study Groups If you are found to be eligible to take part in this study, you will be assigned to a study group based on when you join this study. Up to 3 groups of up to 6 participants will be enrolled in Part 1 of the study, and up ...

Phase

Study of Pembrolizumab in Combination With Ublituximab and TGR-1202 in Patients With Relapsed-refractory CLL

The purpose of this study is to evaluate the safety and effectiveness of pembrolizumab in combination with ublituximab and TGR-1202, in patients with advanced CLL.

Phase